Green Plains vs Rex American Resources
GPRE and REX side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GPRE and REX compare
Rex American Resources is the larger company, worth 1.4 times as much as Green Plains ($1.3B against $953M).
On earnings, Green Plains is cheaper: it trades at 5.5× trailing earnings, against 10.9× for Rex American Resources.
Rex American Resources grew revenue faster over the last twelve months (1.3% versus −19.1% for Green Plains).
Green Plains scores higher on the StockData Score (13 against 12 for Rex American Resources), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GPRE | REX |
|---|---|---|
| Size and price | ||
| Market cap | $953M | $1.3B |
| Share price | $13.59 | $39.93 |
| Change, 1 year | 39.1% | 21.3% |
| Change, 5 years | −66.3% | 174% |
| Beta (5Y) | 0.86 | 0.51 |
| Employees | 642 | 132 |
| StockData Score | ||
| Total score | 13 (better) | 12 |
| Valuation score | 5 (better) | 4 |
| Growth score | 1 | 2 (better) |
| Performance score | 4 (better) | 0 |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 5.5× (better) | 10.9× |
| P/S | 0.5× (better) | 2.0× |
| P/B | 1.0× (better) | 2.0× |
| EV/EBITDA | 4.8× | – |
| P/FCF | 11.9× (better) | 19.3× |
| PEG | – | 0.23 |
| FCF yield | 8.4% (better) | 5.2% |
| Fair value | $67.90 | $61.64 |
| Margin of safety | 80.0% (better) | 35.2% |
| Growth | ||
| Revenue growth (TTM) | −19.1% | 1.3% (better) |
| Revenue growth, 5Y average | 1.7% | 11.8% (better) |
| EPS growth (TTM) | – | 145% |
| EPS growth, 5Y average | – | 98.2% |
| Profitability | ||
| Gross margin | 19.7% | 27.2% (better) |
| Operating margin | 9.3% | – |
| Net margin | 10.9% | – |
| FCF margin | 4.4% | 10.4% (better) |
| Return on equity | 22.9% | – |
| Return on invested capital | 15.4% | – |
| Financial health | ||
| Debt / equity | 0.50 (better) | 0.00 |
| Net debt / EBITDA | 1.21 | – |
| Interest coverage | 5.0× | – |
| Current ratio | 2.31 | 6.88 (better) |
| Altman Z-score | 2.18 | 11.77 (better) |
| Piotroski F-score | 5 | – |
| Dividends and buybacks | ||
| Buyback yield | – | 0.12% |
| Shareholder yield | 0.00% | 0.12% (better) |
| Ownership | ||
| Held by institutions | 111% | 80.3% |
| Held by insiders | 18.1% | 13.1% |
| Insider net buying, 12 months | $101K (better) | −$7.1M |
| Short interest, % of float | 22.7% | 2.4% |
Go deeper
- GPRE stock overview
- GPRE income statement
- GPRE valuation and score
- REX stock overview
- REX income statement
- REX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.